BRCA loss of function including BRCA1 DNA-methylation, but not BRCA-unrelated homologous recombination deficiency, is associated with platinum hypersensitivity in high-grade ovarian cancer

被引:0
作者
Fiegl, Heidelinde [1 ]
Schnaiter, Simon [2 ]
Reimer, Daniel U. [1 ]
Leitner, Katharina [1 ]
Nardelli, Petra [1 ]
Tsibulak, Irina [1 ]
Wieser, Verena [1 ]
Wimmer, Katharina [2 ]
Schamschula, Esther [2 ]
Marth, Christian [1 ]
Zeimet, Alain G. [1 ]
机构
[1] Med Univ Innsbruck, Dept Obstet & Gynecol, Innsbruck, Austria
[2] Med Univ Innsbruck, Inst Human Genet, Innsbruck, Austria
关键词
Ovarian cancer; BRCA1; BRCA2; DNA-methylation; Homologous recombination deficiency (HRD); Platinum sensitivity; PARP inhibitor therapy; PROMOTER METHYLATION; MAINTENANCE THERAPY; BEVACIZUMAB; CARCINOMA; SURVIVAL; CHEMOTHERAPY; SENSITIVITY; MUTATIONS; PHENOTYPE; FREQUENCY;
D O I
10.1186/s13148-024-01781-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background In high-grade ovarian cancer (HGOC), determination of homologous recombination deficiency (HRD) status is commonly used in routine practice to predict response to platinum-based therapy or poly (ADP-ribose) polymerase inhibitors (PARPi). Here we tested the hypothesis that BRCA loss of function (LOF) due to epigenetic or genetic aberrations is a better predictor for the clinical outcome than HRD. One hundred thirty-one HGOC tissues were tested for BRCA DNA-methylation, BRCA mutations, HRD and BRCA1 mRNA expression, followed by a comprehensive survival analysis. Results BRCA1-methylation was detected in 11% of the tumors, exclusively in BRCA1-wild-type (wt) HGOCs. BRCA1-methylated tumors (BRCA1-meth) had HRD-scores similar to those of BRCA-mutated (mut) tumors, and higher compared to unmethylated-BRCA-wt tumors (BRCA-wt-unmeth; P < 0.001). Platinum-refractory or -resistant HGOCs at first recurrence were all BRCA-unmeth cancers. Only one of the BRCA-mut cancers had a platinum-resistant recurrence. Thus, 99% of relapses in cancers with epigenetic or genetic BRCA-alterations were platinum-sensitive. Multivariate analysis confirmed BRCA-LOF as an independent predictor of progression-free survival (PFS) and overall survival (OS), whereas HRD-status had no predictive value for PFS and OS. Patients with BRCA-wt-unmeth cancers had the worst outcome compared to patients with cancers harboring epigenetic or genetic BRCA-alterations (PFS: P = 0.007; OS: P = 0.022). Most importantly, the BRCA-wt-unmeth subfraction of HRD-positive HGOCs exhibited the same poor survival as the entire HRD-negative cohort. Conclusion In HGOC BRCA mutational status together with BRCA1-methylation exhibit the best predictive power for favorable clinical outcome and thus high sensitivity to platinum-based therapy, whereas BRCA-unrelated HRD positivity was not associated with improved platinum sensitivity.
引用
收藏
页数:10
相关论文
共 35 条
  • [1] Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer
    Abkevich, V.
    Timms, K. M.
    Hennessy, B. T.
    Potter, J.
    Carey, M. S.
    Meyer, L. A.
    Smith-McCune, K.
    Broaddus, R.
    Lu, K. H.
    Chen, J.
    Tran, T. V.
    Williams, D.
    Iliev, D.
    Jammulapati, S.
    FitzGerald, L. M.
    Krivak, T.
    DeLoia, J. A.
    Gutin, A.
    Mills, G. B.
    Lanchbury, J. S.
    [J]. BRITISH JOURNAL OF CANCER, 2012, 107 (10) : 1776 - 1782
  • [2] Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer
    Aghajanian, Carol
    Goff, Barbara
    Nycum, Lawrence R.
    Wang, Yan V.
    Husain, Amreen
    Blank, Stephanie V.
    [J]. GYNECOLOGIC ONCOLOGY, 2015, 139 (01) : 10 - 16
  • [3] BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation-Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
    Alsop, Kathryn
    Fereday, Sian
    Meldrum, Cliff
    deFazio, Anna
    Emmanuel, Catherine
    George, Joshy
    Dobrovic, Alexander
    Birrer, Michael J.
    Webb, Penelope M.
    Stewart, Colin
    Friedlander, Michael
    Fox, Stephen
    Bowtell, David
    Mitchell, Gillian
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (21) : 2654 - 2663
  • [4] Baldwin RL, 2000, CANCER RES, V60, P5329
  • [5] Integrated genomic analyses of ovarian carcinoma
    Bell, D.
    Berchuck, A.
    Birrer, M.
    Chien, J.
    Cramer, D. W.
    Dao, F.
    Dhir, R.
    DiSaia, P.
    Gabra, H.
    Glenn, P.
    Godwin, A. K.
    Gross, J.
    Hartmann, L.
    Huang, M.
    Huntsman, D. G.
    Iacocca, M.
    Imielinski, M.
    Kalloger, S.
    Karlan, B. Y.
    Levine, D. A.
    Mills, G. B.
    Morrison, C.
    Mutch, D.
    Olvera, N.
    Orsulic, S.
    Park, K.
    Petrelli, N.
    Rabeno, B.
    Rader, J. S.
    Sikic, B. I.
    Smith-McCune, K.
    Sood, A. K.
    Bowtell, D.
    Penny, R.
    Testa, J. R.
    Chang, K.
    Dinh, H. H.
    Drummond, J. A.
    Fowler, G.
    Gunaratne, P.
    Hawes, A. C.
    Kovar, C. L.
    Lewis, L. R.
    Morgan, M. B.
    Newsham, I. F.
    Santibanez, J.
    Reid, J. G.
    Trevino, L. R.
    Wu, Y. -Q.
    Wang, M.
    [J]. NATURE, 2011, 474 (7353) : 609 - 615
  • [6] Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents
    Birkbak, Nicolai J.
    Wang, Zhigang C.
    Kim, Ji-Young
    Eklund, Aron C.
    Li, Qiyuan
    Tian, Ruiyang
    Bowman-Colin, Christian
    Li, Yang
    Greene-Colozzi, April
    Iglehart, J. Dirk
    Tung, Nadine
    Ryan, Paula D.
    Garber, Judy E.
    Silver, Daniel P.
    Szallasi, Zoltan
    Richardson, Andrea L.
    [J]. CANCER DISCOVERY, 2012, 2 (04) : 366 - 375
  • [7] Clinical Relevance of BRCA1 Promoter Methylation Testing in Patients with Ovarian Cancer
    Blanc-Durand, Felix
    Tang, Roseline
    Pommier, Margaux
    Nashvi, Marzieh
    Cotteret, Sophie
    Genestie, Catherine
    Le Formal, Audrey
    Pautier, Patricia
    Michels, Judith
    Kfoury, Maria
    Herve, Robert
    Mengue, Sylvie
    Wafo, Estelle
    Elies, Antoine
    Miailhe, Gregoire
    Uzan, Jennifer
    Rouleau, Etienne
    Leary, Alexandra
    [J]. CLINICAL CANCER RESEARCH, 2023, 29 (16) : 3124 - 3129
  • [8] Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
    Burger, Robert A.
    Brady, Mark F.
    Bookman, Michael A.
    Fleming, Gini F.
    Monk, Bradley J.
    Huang, Helen
    Mannel, Robert S.
    Homesley, Howard D.
    Fowler, Jeffrey
    Greer, Benjamin E.
    Boente, Matthew
    Birrer, Michael J.
    Liang, Sharon X.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (26) : 2473 - 2483
  • [9] Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer:: correlation with disease characteristics
    Catteau, A
    Harris, WH
    Xu, CF
    Solomon, E
    [J]. ONCOGENE, 1999, 18 (11) : 1957 - 1965
  • [10] Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancer
    Coelho, Ricardo
    Tozzi, Alessandra
    Disler, Muriel
    Lombardo, Flavio
    Fedier, Andre
    Lopez, Monica Nunez
    Freuler, Florian
    Jacob, Francis
    Heinzelmann-Schwarz, Viola
    [J]. CELL DEATH & DISEASE, 2022, 13 (10)